Summary

The Single Tablet Regimen (STaR) head-to-head comparison of anti-HIV-1 formulations has established the noninferiority of rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) versus efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF) in HIV-1 virologic outcomes at weeks 48 and 96. The RPV/FTC/TDF combination was superior to EFV/FTC/TDF in terms of adverse effects and patient-reported outcomes.